Maastricht, The Netherlands, April 28, 2016 – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. He will be responsible for the clinical strategy and development of Cristal Therapeutics’ range of nanomedicines. […]

Maastricht, The Netherlands, July 14, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology […]

Maastricht, The Netherlands, 22 May 2014 – Cristal Therapeutics, today announced the appointments of Prof. Dr. Rob Liskamp, Prof. Dr. Twan Lammers, Prof. Dr. Alberto Gabizon, Dr. Maninder Hora and Dr. William Zamboni to its new Scientific Advisory Board. Cristal Therapeutics is a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases, such […]

Maastricht, The Netherlands, December 15, 2014 – Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding […]

Maastricht, The Netherlands, July 1, 2013 – Cristal Therapeutics, the new trade name of the Dutch nanomedicine company Cristal Delivery B.V., announces the successful expansion of the financing round initiated by Thuja Capital and BioGeneration Ventures, by adding two additional investors, being Nedermaas Ventures and Innovatie Fonds Limburg. The proceeds of this round will allow Cristal […]